https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-10 / J Hematol Oncol 2010 Feb;3:7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-10 / J Hematol Oncol 2010 Feb;3:72010-02-10 00:00:002010-02-10 00:00:00Ovarian cancer immunotherapy: opportunities, progresses and challenges
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Int J Hyperthermia 2010;26(2):118-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Int J Hyperthermia 2010;26(2):118-262010-01-01 00:00:002010-01-01 00:00:00Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Expert Opin Biol Ther 2009 Jun;9(6):677-88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Expert Opin Biol Ther 2009 Jun;9(6):677-882009-06-01 00:00:002019-02-15 08:52:19Cellular immunotherapy for ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-12-06 / Gynecol. Oncol. 2009 Feb;112(2):384-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-12-06 / Gynecol. Oncol. 2009 Feb;112(2):384-82008-12-06 00:00:002008-12-06 00:00:00Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – a phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-01 / Anticancer Res. 2008 Sep-Oct;28(5B):3135-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-01 / Anticancer Res. 2008 Sep-Oct;28(5B):3135-82008-09-01 00:00:002008-09-01 00:00:00Ovarian cancer detection and treatment: current situation and future prospects
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-01 / Expert Rev Anticancer Ther 2008 Feb;8(2):243-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-01 / Expert Rev Anticancer Ther 2008 Feb;8(2):243-572008-02-01 00:00:002019-02-15 08:52:23Immunotherapy opportunities in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-05-01 / Lancet Oncol. 2007 May;8(5):451-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-05-01 / Lancet Oncol. 2007 May;8(5):451-42007-05-01 00:00:002007-05-01 00:00:00Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-10-23 / Clin. Immunol. 2007 Jan;122(1):18-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-10-23 / Clin. Immunol. 2007 Jan;122(1):18-272006-10-23 00:00:002019-02-15 08:52:20In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Cancer Gene Ther. 2006 Feb;13(2):182-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Cancer Gene Ther. 2006 Feb;13(2):182-932006-02-01 00:00:002006-02-01 00:00:00Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / Minerva Ginecol 2004 Dec;56(6):515-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / Minerva Ginecol 2004 Dec;56(6):515-272004-12-01 00:00:002004-12-01 00:00:00Current approaches in ovarian cancer vaccines
